We’re presenting 4 abstracts on Trudhesa® nasal spray, including assessments on drug-drug interactions with #gepants, at #AAN23. Looking forward to sharing new insights on acute #migraine treatment with the #neurology community in Boston! Learn more: investors.impelpharma.com/news-releases/…

We’re presenting a range of new data at #AANAM suggesting Trudhesa is safe to use when co-administered with commonly prescribed migraine mediations, including a new analysis that predicts no DDIs when co-administered with #gepants. Learn more: investors.impelpharma.com/news-releases/…

Stop by our booth #1778 at #AANAM to learn about our latest #migraine data. #AAN23 #BrainHealth #NeuroTwitter @AANMember

Today at #AANAM we’re presenting an analysis using a model-based approach that found no DDIs of clinical concern are theoretically predicted if Trudhesa and gepants are co-administered within recommended clinical doses. Abstract: aan.com/MSA/Public/Eve… #NeuroTwitter #migraine

Today at #AANAM we’re presenting an analysis in a small population from our pivotal STOP 301 study in acute #migraine that found no significant safety concerns emerged from off-protocol, concomitant use of triptans and Trudhesa. Abstract: aan.com/MSA/Public/Eve…

This morning we announced the appointment of Michael Kalb as Chief Financial Officer, effective immediately. Read our press release to learn more about his broad corporate and financial experience and plans to continue creating value for our shareholders: investors.impelpharma.com/news-releases/…

Join us on TOMORROW at 8:30am ET to learn more about our Q1 2023 #earnings and business updates. A replay of the webcast and accompanying slides will be available on our website following. Access the live conference call by registering: investors.impelpharma.com/events/event-d… $IMPL

This morning we're reporting our Q1 2023 financial results and providing a business update. Join our live webcast TODAY at 8:30am ET to discuss them. Access the webcast, slides, and replay here: investors.impelpharma.com/events/event-d… Press release: investors.impelpharma.com/news-releases/… $IMPL

We’re kicking off #MHAM with a MUST READ on Migraine At Work Day. Published in 2021 by Harvard Business Review, Dr. Olivia Begasse de Dhaem’s (Olivia Begasse de Dhaem, MD, FAHS (she/her)) article outlines research-backed strategies to help raise awareness and support employees with #migraine. hbr.org/2021/02/migrai…

During #MHAM, we honor those we’ve lost to migraine/headache disease. Please light a candle or light your home with a purple light today at 6pm ET in remembrance. Then take a picture and share it on social media with #ShineALight. #mham2023 #EducateYourself #EducateOthers

#Migraine diaries are also a great tool to evaluate how your current meds are working for you, and to arm yourself with the information needed to become a self-advocate. Thanks National Headache Foundation (NHF)! #MHAM

We’re presenting new real-world data at #AHSAM suggesting concomitant preventive & acute medication use decreases in patients with #migraine using Trudhesa® (DHE mesylate) nasal spray. Learn more about our data: investors.impelpharma.com/news-releases/… #NeuroTwitter #MHAM

Excellent meeting #Women’s Health #AHSAM ⁦American Headache Society⁩ Fantastic discussion #Migraine #Hormones #AHSFirstContact collaboration ⁦Women Neurologists Group⁩ ⁦American Academy of Neurology⁩ ❤️🧠⁦Miles For Migraine⁩ #EMC

Preliminary real-world data at #AHSAM suggest that concomitant preventive & acute medication use generally decreases in patients taking Trudhesa® (DHE mesylate) nasal spray, and that use of antinausea medications (common with DHE administered via IV) did not increase.

If you're at American Headache Society's Scientific Meeting today, join HMPF at 3:30 CT for a claims data analysis of the effect of barriers to treatment access on emergency department usage by race/ethnicity in the U.S. Learn more: bit.ly/3J0YZE8

A second poster on preliminary real-world data at #AHSAM underscores the need for non-oral treatment options for #migraine given the prevalence of pre-existing #gastrointestinal disorders among those prescribed with Trudhesa® (DHE mesylate).

The Impel team proudly supports the #migraine community. Today we're wearing our #ShadesForMigraine to raise awareness about this complex, neurological disease that's more than just a #headache. #MHAM #MigraineAwareness Shades for Migraine

Trudhesa® (DHE mesylate) delivers a trusted #migraine therapeutic to the vascular-rich upper nasal space via the POD® device. This results in IV-like efficacy at home - not via injection in an ER. Learn more from WebMD: webmd.com/drug-medicatio…

Summer is a tough time of year for #migraine and #headaches. To best celebrate #freedom with your friends and family, be mindful of your triggers and keep your acute meds on hand. Wishing everyone a safe and happy #IndependenceDay!

In 2021, the FDA approved a new way of delivering dihydroergotamine that targets the upper nasal space for migraine. Why is this novel delivery method unique & what #migraine types is it most effective for? migrainedisorders.org/migraine-treat…… Article sponsored by Impel Pharmaceuticals